LEADER 01929nam  22004331  450 
001 9910678471803321
005 20180103162434.3
010   $a1-5264-3112-2
035   $a(CKB)4100000001482268
035   $a(OCoLC)1023546327
035   $a(CaToSAGE)SAGE000003238
035   $a(EXLCZ)994100000001482268
100   $a20180103e20172017  fy|            0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAmgen $elaunching Repatha /$fTim Calkins, Mike Harris
210  1$aLondon :$cKellogg School of Management,$d2017.
215   $a1 online resource $cillustrations
225 1 $aSAGE Knowledge. Cases
300   $aOriginally published in Calkins, T., & Harris, M. (2017). Amgen: Launching Repatha. 5-416-759. Evanston, IL: Kellogg School of Management at Northwestern University.
330 8 $aIn March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast.
410  0$aSAGE Knowledge.$pCases.
606   $aHeart$xDiseases$xTreatment$zUnited States
606   $aHypercholesteremia
615  0$aHeart$xDiseases$xTreatment
615  0$aHypercholesteremia.
676   $a616.12
700   $aCalkins$b Tim$0507376
702   $aHarris$b Mike
801  0$bCaToSAGE
801  1$bCaToSAGE
801  2$bUtOrBLW
906   $aBOOK
912   $a9910678471803321
996   $aAmgen$93073104
997   $aUNINA